TWI874616B - Ｔａａｒ１促效劑的鹽類及結晶形式 - Google Patents

Ｔａａｒ１促效劑的鹽類及結晶形式 Download PDF

Info

Publication number
TWI874616B
TWI874616B TW110109520A TW110109520A TWI874616B TW I874616 B TWI874616 B TW I874616B TW 110109520 A TW110109520 A TW 110109520A TW 110109520 A TW110109520 A TW 110109520A TW I874616 B TWI874616 B TW I874616B
Authority
TW
Taiwan
Prior art keywords
methyl
ethyl
pyrazole
phenyl
carboxamide
Prior art date
Application number
TW110109520A
Other languages
English (en)
Chinese (zh)
Other versions
TW202140466A (zh
Inventor
克里斯藤 安卓 葛雷瑟
厄爾 舒維特
法蘭克 史都瓦舍
芙洛恩斯 妮可 安東妮爾特 提克斯恩特
蕾尼 楚莎迪
Original Assignee
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW202140466A publication Critical patent/TW202140466A/zh
Application granted granted Critical
Publication of TWI874616B publication Critical patent/TWI874616B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW110109520A 2020-03-19 2021-03-17 Ｔａａｒ１促效劑的鹽類及結晶形式 TWI874616B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20164069 2020-03-19
EP20164069.5 2020-03-19

Publications (2)

Publication Number Publication Date
TW202140466A TW202140466A (zh) 2021-11-01
TWI874616B true TWI874616B (zh) 2025-03-01

Family

ID=69846246

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110109520A TWI874616B (zh) 2020-03-19 2021-03-17 Ｔａａｒ１促效劑的鹽類及結晶形式

Country Status (13)

Country Link
US (1) US20230120311A1 (https=)
EP (1) EP4121428B1 (https=)
JP (2) JP2023517729A (https=)
KR (1) KR20220155575A (https=)
CN (1) CN115279752A (https=)
AU (1) AU2021238632A1 (https=)
BR (1) BR112022016746A2 (https=)
CA (1) CA3166331A1 (https=)
ES (1) ES3044409T3 (https=)
IL (1) IL294301A (https=)
MX (1) MX2022010794A (https=)
TW (1) TWI874616B (https=)
WO (1) WO2021185878A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023323858A1 (en) * 2022-08-12 2024-11-21 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising 5-ethyl-4-methyl- n-[4-[(2 s) morpholin-2-yl]phenyl]-1h-pyrazole-3-carboxamide
WO2024222860A1 (zh) * 2023-04-28 2024-10-31 江苏豪森药业集团有限公司 一种吗啉杂环类化合物的盐及其制备方法和应用
CN117903050B (zh) * 2024-03-15 2024-05-17 中国药科大学 阿立哌唑共晶及其药物组合物和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017157873A1 (en) * 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017157873A1 (en) * 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
專書 Caira M.R. et al. "Crystalline Polymorphism of Organic Compounds." vol 198:163-208, In: Weber E. et al. (eds) Design of Organic Solids. Topics in Current Chemistry.Springer, Berlin, Heidelberg. First Online: 01 January 1999.; *
期刊 Richard J. Bastin, et al. " Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities." Org. Proc. Res. 4, 5, Dev. 2000, 427-435. *

Also Published As

Publication number Publication date
JP2023517729A (ja) 2023-04-26
CA3166331A1 (en) 2021-09-23
EP4121428A1 (en) 2023-01-25
BR112022016746A2 (pt) 2022-10-11
WO2021185878A1 (en) 2021-09-23
KR20220155575A (ko) 2022-11-23
US20230120311A1 (en) 2023-04-20
EP4121428B1 (en) 2025-08-13
IL294301A (en) 2022-08-01
AU2021238632A1 (en) 2022-07-14
TW202140466A (zh) 2021-11-01
ES3044409T3 (en) 2025-11-26
EP4121428C0 (en) 2025-08-13
CN115279752A (zh) 2022-11-01
MX2022010794A (es) 2022-09-27
JP2025166092A (ja) 2025-11-05

Similar Documents

Publication Publication Date Title
TWI874616B (zh) Ｔａａｒ１促效劑的鹽類及結晶形式
WO2019191620A1 (en) Crystalline forms of modulators of cftr
AU2018303293B2 (en) Amorphous form of vilanterol trifenatate and processes for the preparation thereof
US9259403B2 (en) Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
JP5997162B2 (ja) アプレピタントｌ−プロリン組成物および共結晶
JP2024517608A (ja) 結晶性カルバゾール誘導体
AU2020289738A1 (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of Alzheimer's Disease
HK40074347A (en) Salts and crystalline forms of a taar1 agonist
WO2019246479A1 (en) Form of ponatinib
WO2024009977A1 (ja) ５Ｈ－ピロロ［２，３－ｄ］ピリミジン－６（７Ｈ）－オン及びその塩体の結晶
WO2025035486A1 (zh) 一种酪氨酸激酶抑制剂的可药用盐、结晶形式及其制备方法
CA3255634A1 (en) Crystalline forms of 4-[(5-chloropyridin-2-yl)methoxy]-1-[3-(propan-2-yl)-1h,2h,3h,4h,5h-[1,4]diazepino[1,7-a]indol-9-yl]-1,2-dihydropyridin-2-one and salts thereof, method of preparation, and uses thereof
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途
HK1187554B (en) Aprepitant l-proline composition and cocrystal